Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon has been listed in the 2021 "Top 20 CXO (including CDMO) Enterprises in China" for 4 consecutive years

Page View:

On July 12, the 2021 "Top 20 CXO (including CDMO) Enterprise in China" selected by Menet was officially released, which once again demonstrated the professionalism and influence of a strong enterprises in China's pharmaceutical industries.

Shanghai Medicilon Inc. (Medicilon) was listed in the "Top 20 CXO (including CDMO) Enterprises in China".  This is the 4th consecutive year that Medicilon has won this honor.

Top 20 CXO (including CDMO) Enterprises in China.jpg

It is understood that the "Top 100 List of China's Pharmaceutical Industry" has become one of the most concerned and authoritative pharmaceutical rankings in China for more than 10 consecutive years.

Medicilon was listed in the "Top 20 CXO (including CDMO) Enterprises in China", which is the inevitable result of Medicilon's 18 years of rooting in new drug research and development and concentrating on technological innovation.  It is also highly affirmed by professional institutions and industries to Medicilon's innovation driving force and brand influence.

    Medicilon’s CDMO Service Platform

Medicilon has constructed the GMP Drug Products Pilot Plant to meet the rising needs for innovative medicine R&D, production, packaging, inspections and stability tests. We are aiming for qualified CDMO services for clients with requirements for the development of innovative medicine.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.

You may be interested in the following articles:

Relevant newsRelevant news